Cancer BiologybioRxiv
Novel EGFR-Mutant Mouse Models of Lung Adenocarcinoma Reveal Adaptive Immunity Requirement for Durable Osimertinib Response
DOI 10.1016/j.canlet.2023.216062
Author
E. K. Kleczko
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagActivity by Year
2022-2022 · peak 4/yrCo-Author Collaboration Network
10 top collaborators · 33 mutual co-author linksFocal author (center)Selected co-authorORCID co-authorUnlinked name
Curved chords = mutual co-authorship4 papers
Recent·Most cited
- Cancer BiologybioRxiv
Evaluation of KRASG12C Inhibitor Responses in Novel Murine KRASG12C Lung Cancer Cell Line Models
D. J. Sisler, T. K. Hinz, A. T. Le…·L. E. Heasley
This paper develops three novel murine KRASG12C-driven lung cancer cell lines to evaluate responses to KRASG12C inhibitors and identify combination strategies for improved therapeutic outcomes.
DOI 10.3389/fonc.2023.1094123 - ImmunologybioRxiv
Immune Checkpoint Activity Regulates Polycystic Kidney Disease Progression
E. K. Kleczko, D. T. Nguyen, K. H. Marsh…·K. Hopp
This study investigates immune checkpoint activity in ADPKD, finding that dual checkpoint inhibition improves disease outcomes in adult-onset models.
DOI 10.1172/jci.insight.161318 - Cancer BiologybioRxivPreprint
Adaptive immunity is required for durable responses to alectinib in murine models of EML4-ALK lung cancer
E. K. Kleczko, T. K. Hinz, T. T. Nguyen…·R. A. Nemenoff
This paper shows that adaptive immunity enhances the durability of alectinib response in EML4-ALK lung cancer models, with CD8+ T cells playing a key role.
DOI 10.1101/2022.04.14.488385